51 studies found for:    Open Studies | "Cytomegalovirus Infections"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Unknown  Comparison of Two Immunosuppressive Regimens in Kidney Transplant Recipients With Deceased Donors With the Aim of Preventing the Development of Fibrosis / Atrophy of Reducing the Incidence of Cytomegalovirus Infection
Conditions: Disorder of Transplanted Kidney;   Cytomegalovirus Infections
Intervention:
2 Recruiting Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporineversus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A
Conditions: Transplantation Infection;   Cytomegalovirus Infection
Interventions: Drug: Everolimus;   Drug: mycophenolic acid
3 Recruiting Evaluation of the PK and PD of Ganciclovir in Premature Infants Receiving Treatment for CMV Infection
Condition: Cytomegalovirus Infections
Intervention:
4 Recruiting A Study of RG7667 for the Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients
Condition: Cytomegalovirus Infections
Interventions: Drug: RG7667;   Drug: Placebo
5 Recruiting Diagnosis of Congenital CMV Infection in Neonates Who Failed Newborn Hearing Screening
Condition: Congenital Cytomegalovirus Infection
Intervention: Other: CMV PCR
6 Recruiting MSC for Treatment of CMV Infection
Conditions: Stem Cell Transplantation, Hematopoietic;   CMV Infection;   Hematological Diseases
Intervention: Biological: MSCs
7 Recruiting A French Cohort of Transplant Recipients With CMV Infection : Risk Factors for Antiviral Resistance in the Prophylaxis Era.
Condition: Transplant Recipients With CMV Infection
Intervention: Biological: CMV Infection
8 Unknown  Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients
Condition: Cytomegalovirus Disease
Interventions: Drug: Certican (everolimus) + valganciclovir;   Drug: Valganciclovir
9 Recruiting A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)
Conditions: Congenital Cytomegalovirus Infection;   Maternal Cytomegalovirus Infection
Intervention: Drug: CMV hyperimmune globulin
10 Recruiting Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
Conditions: CMV Infection;   Persistent CMV Viremia
Intervention: Genetic: CMVpp65 Specific T-cells
11 Recruiting Immunological Characteristics of Maternal-fetal Transmission of Cytomegalovirus in Pregnancy
Conditions: Pregnancy;   Cytomegalovirus Infections;   Congenital Infection
Intervention:
12 Recruiting Cytomegalovirus-Specific Response Measured by QuantiFeron® and Overall Immunologic Response Measured by ImmuKnow® in Lung Transplant Patients CMV-positive
Condition: Cytomegalovirus Infections
Intervention:
13 Not yet recruiting SUSTAIN: A Randomized, Double-Blind, Multicenter, Phase 3 Study of the Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease in CMV Seronegative Kidney Allograft Recipients
Condition: Cytomegalovirus Disease
Interventions: Drug: Brincidofovir;   Drug: Valganciclovir
14 Unknown  Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy
Conditions: Heart Transplantation;   Cardiac Allograft Vasculopathy;   Cytomegalovirus Infection
Interventions: Drug: Pre-emptive strategy with valganciclovir plus everolimus;   Drug: Prophylaxis with valganciclovir plus mycophenolate;   Drug: Prophylaxis with valganciclovir plus everolimus;   Drug: Pre-emptive mycophenolate
15 Not yet recruiting Evaluation of Early Use of Everolimus (EVE) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients
Condition: Cytomegalovirus Infections
Interventions: Drug: Everolimus+Tacrolimus+Prednisone;   Drug: Mycophenolate+Tacrolimus+Prednisone
16 Unknown  Genotyping of Cytomegalovirus From Patients in Israel
Condition: Cytomegalovirus Infections
Intervention:
17 Not yet recruiting Most Closely Human Leukocyte Antigen (HLA)-Matched CMV-specific T Lymphocytes (Viralym-C)
Condition: CMV Infections
Intervention: Biological: Viralym-C
18 Unknown  Evaluation of the Safety and Efficacy of Standard Intravenous Immunoglobulins in Pregnant Women With Primary Cytomegalovirus Infection
Condition: Cytomegalovirus Congenital Infection
Intervention: Biological: standard intravenous immunoglobulin
19 Recruiting Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Allo-HSCT Recipients
Conditions: Cytomegalovirus Infection;   GVHD
Intervention:
20 Recruiting An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
Conditions: Healthy Subjects;   Cytomegalovirus Infection;   Dialysis
Interventions: Drug: ASP0113;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years